Navigation Links
Oncolytics Biotech(R) Inc. Announces Publication of Phase I Clinical Trial Results in Clinical Cancer Research
Date:5/18/2010

EOLYSIN, its proprietary formulation of the human reovirus. For further information about Oncolytics, please visit: www.oncolyticsbiotech.com.

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the implication of the materials presented in "Clinical Cancer Research" with respect to REOLYSIN, and the Company's belief as to the potential of REOLYSIN as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN as a cancer treatment, the tolerability of REOLYSIN outside a controlled test, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN, uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements, except as required by applicable laws.


'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Oncolytics Biotech(R) Inc. Announces First Quarter 2010 Results
2. Oncolytics Biotech(R) Inc. Announces Details of 2010 Annual Shareholder Meeting
3. Oncolytics Biotech(R) Inc. Completes Patient Enrollment in Phase I Portion of U.S. Phase I/II Recurrent Malignant Gliomas Clinical Trial
4. Oncolytics Biotech(R) Inc. Receives Approval from the U.K. MHRA to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
5. Oncolytics Biotech(R) Inc. Appoints Senior Vice President, Global Licensing and Business Development
6. Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters Over-Allotment Option
7. Oncolytics Biotech(R) Inc. Announces Unit Offering
8. Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase I/II Trial Results in Advanced Solid Cancers with a Focus on the Head and Neck at the AACR-NCI-EORTC Meeting
9. Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting
10. Oncolytics(R) Biotech Inc. Announces Issuance of 33rd U.S. Patent
11. Media Advisory - Oncolytics Biotech Inc. to Present at BIO Investor Forum 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... 3, 2015 /PRNewswire/ - BioAmber Inc. (NYSE: ... today announced it has initiated commissioning activities for its ... Sarnia, Ontario , Canada.  ... months, with the facility being in commercial operation in ... in two months and it is carrying out commissioning ...
(Date:3/3/2015)... 03, 2015 GlobalStemCellsGroup.com has ... Camacho Alcocer, a biomedical researcher and founding partner of ... GSCG’s team of biomedical professors who will teach the ... Criogenix SA de CV is a private company registered ... and Companies in Mexico (RENIECYT). , Camacho Alcocer will ...
(Date:3/2/2015)... MD and Fort Washington, PA (PRWEB) March 02, 2015 ... Genetics (ASHG) and ReachMD announced today ... of audio interviews designed to educate healthcare professionals on ... management. , The series features peer-to-peer interviews ... topics such as:, ,     Translational Genomics and ...
(Date:3/2/2015)... In the five years to 2015, the ... growth. The industry, which consists of companies that perform ... other goods, has grown on account of an improving ... IBISWorld forecasts that industry revenue will increase at an ... the five-year period, including an anticipated increase of 2.8% ...
Breaking Biology Technology:BioAmber Begins Commissioning of Sarnia Commercial Plant 2BioAmber Begins Commissioning of Sarnia Commercial Plant 3Mario Camacho Alcocer Joins Global Stem Cells Group Faculty 2Mario Camacho Alcocer Joins Global Stem Cells Group Faculty 3American Society of Human Genetics (ASHG) and ReachMD Launch Series on Genetics and Genomics 2American Society of Human Genetics (ASHG) and ReachMD Launch Series on Genetics and Genomics 3Laboratory Testing Services in Canada Industry Market Research Report Now Available from IBISWorld 2Laboratory Testing Services in Canada Industry Market Research Report Now Available from IBISWorld 3
... leader in room,temperature biological sample stabilization, announced today that ... Sales and Marketing.,Biomatrica,s interim Vice President of Sales and ... company and will continue to serve as,an advisor on ... years of sales and marketing experience in,the biotech industry. ...
... of 98% in net earnings from continuing operations during the first ... 2008 to reach 10.5 million US dollars ... All amounts in US dollars, QUEBEC ... developer, manufacturer and marketer of,added value products for health and nutrition industries, ...
... NeoGenomics, Inc. (OTC,Bulletin Board: NGNM) announced today that it ... May 7, 2008., The Company has scheduled a ... May 7, 2008, at 11:00 AM EDT. Interested investors ... minutes prior to the call. A replay of the ...
Cached Biology Technology:Trisha Dowling Joins Biomatrica as Vice President, Sales and Marketing 2Atrium shows a strong financial performance for its first quarter 2Atrium shows a strong financial performance for its first quarter 3Atrium shows a strong financial performance for its first quarter 4Atrium shows a strong financial performance for its first quarter 5NeoGenomics Schedules Its Q1 2008 Earnings Release for May 7, 2008 2
(Date:2/5/2015)... January 28, 2015 New Market ... And Segment Forecasts To 2020 has Been Added to ... market is expected to reach USD 5.10 billion by ... Research, Inc. IR cameras help identify the site of ... to witness surging demand in medical imaging applications. They ...
(Date:1/22/2015)... Markets ( http://www.researchandmarkets.com/research/4trb7t/biometrics_a ) has announced the addition ... report to their offering. , The primary ... is who she/he is claiming to be, and for this ... physical characteristics, such as fingerprint, hand or palm print, iris, ...
(Date:1/22/2015)... MADISON, Wis. , Jan. 15, 2015  BellBrook ... for drug discovery, announced the launch of a ... of the company,s Transcreener UDP Assay, a high ... enzymes. The new assay will allow for sensitive ...
Breaking Biology News(10 mins):IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2
... has been the inspiration for countless books and movies, ... engineers. Researchers at the California Institute of Technology (Caltech) ... intelligencenot in a robot or a silicon chip, but ... to have made an artificial neural network out of ...
... Mobile devices have become as common as the stethoscope in ... read test results, access diagnostic tools and take patient notes, ... smartphone or using a flash drive. These mobile devices are ... huge security risks to patient information. In less ...
... LOS ALAMOS, New Mexico, July 20, 2011Researchers at the ... Great Lakes Bioenergy Research Center have found a potential ... materials such as corn leaves and stalks, or switch ... Journal of the American Chemical Society , Los Alamos ...
Cached Biology News:Caltech researchers create the first artificial neural network out of DNA 2Caltech researchers create the first artificial neural network out of DNA 3Caltech researchers create the first artificial neural network out of DNA 4Mobile Devices Pose New Security Risks for Patients; Five Experts Share Insights on mHealth 2Mobile Devices Pose New Security Risks for Patients; Five Experts Share Insights on mHealth 3Mobile Devices Pose New Security Risks for Patients; Five Experts Share Insights on mHealth 4Mobile Devices Pose New Security Risks for Patients; Five Experts Share Insights on mHealth 5Researchers find potential key for unlocking biomass energy 2
Co-precipitant is free of background polynucleotides,Dnases,Rnases, proteases. 20mg/ml...
Can be used for the quantitative recovery of small amounts of nucleic acids within dilute solutions. 5mg/ml...
RAB32, member RAS oncogene family, mRNA (cDNA clone MGC:13500 IMAGE:4280407), complete cds...
Can be used for the quantitative recovery of small amounts of nucleic acids within dilute solutions. 5mg/ml...
Biology Products: